#TREATME
Check out the charts for #longCOVID & #MECFS to see how enzymes like NK stacked up against aspirin, Plavix, DOACs (example: apixaban), and heparin. I won't do a deep dive until I gather more data & close the survey but wanted to share some data so far!🧵
Very Quick thoughts: 1) Oral anticoagulants alone looks subpar in #pwLC likely bc they only prevent clot formation & don't degrade existing microclots. Goal is to give body a break so it may clear clots on its own, but some may be too sick to achieve this.
1) cont..
Also note small sample size, so can't draw strong conclusions yet.
2) Many #pwLC may have hyperactivated platelets so it would stand to reason than antiplatelet meds would help. While just 38% reported aspirin ALONE helped, 60% benefited from dual antiplatelet therapy.
3) In #pwME, sample sizes were much smaller so I was unable to break down as many subgroups. I really need more #pwME to answer this survey. I know you're out there. 🥰 But it's interesting to note that HEPARIN was a shining star in both #pwME & #pwLC, helping almost 75%!
3) continued:
In #pwLC who took heparin + antiplatelets, 9 in 11 (82%) reported benefits & 87.5% reported "quite a few" of their symptoms significantly improved. Not sure why heparin might work better than oral anticoagulants. More studies with more participants needed obvs.
4) Quite a few w/ antiphospholipid syndrome are taking direct oral anticoagulants (DOACs). A large study came out last month concluding that those w/ APS should be on warfarin and not DOACs due to ⬆️ risk of clots in the latter. Talk w/ your dr about this. jacc.org/doi/10.1016/j.…
5) NK & LK +/- SP stack up well here. No surprise considering that NK & LK directly degrade fibrin in clots whereas anticoagulants only prevent clot formation. ~65% improved on NK+SP (n=167) & LK (n=39). This doesn't even consider dose or formulation, so 65% is extra impressive.
6) Notably, 41% of lumbro respondents took Boluoke, the gold standard for LK, & none reported feeling worse. Respondents reported best results w/ Boluoke vs other LK brands. Almost 66% & 75% of #pwME & #pwLC who paired LK with SP or took LK + NK + SP improved.
There's lots more to go into, but I was excited & wanted to share a general overview of what I'm seeing so far in these treatments.😊If you know any #pwME or #pwLC on anticoagulants, antiplatelets, or NK/LK/SP, pls direct them to my #TREATME survey. surveymonkey.com/r/TREATMEANDLC
Disclaimer:
Remember this is all preliminary data & I'm not considering durations of treatment, doses or formulations here. I will do all that at a later date once I get more data.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Reviewing preliminary data from the survey (n=1,750!), here are some early observations on a few treatments:
1) Both #pwLC and #pwME benefit remarkably similarly from LDN. Check out the almost identical survey results for overall benefit & number of symptoms improved.
2) People are more likely to benefit from CoQ10 at doses 200 mg or higher, but even then, their overall condition improves only slightly.
2) Both #pwME & #pwLC benefit from anticoagulants (more on this another time - very interesting stuff!).
3) There is a clear increase in benefit when adding on antiplatelets to anticoagulants, but aspirin alone does not help many (78/255).
4) Interestingly, HEPARIN may be more beneficial in both pwME & pwLC than direct oral anticoagulants.
TREAT ME covers 150+ medications & supplements. Treatments were selected based on published trials, case reports, other relevant studies, results of earlier surveys I’ve written, direct patient accounts (incl lots of feedback from many of YOU🥰), and my own pharmacist intuition.
The survey has been granted IRB exemption.👍
Furthermore, @OpenMedF will be reviewing a summary of the survey results as they gather info for prospective research studies🤩😍
PLEASE join this effort to investigate #ME & #LongCOVID treatments!
🚨When assessing cardiovascular risk, history of COVID should be considered a risk factor for cardiovascular disease.
Official treatment guidelines should be updated to account for frequent SARS-CoV-2 reinfections & Long COVID.🧵 jamanetwork.com/journals/jama/…
For example:
This atherosclerotic cardiovascular disease (ASCVD) risk calculator estimates the 10-year risk of ASCVD.
One problem: the tool does NOT consider history of COVID & thus likely underestimates risk in this enormous new population.
👇 tools.acc.org/ASCVD-Risk-Est…
The risk calculator is often used to help guide therapy decisions. For example, USPSTF determined that for primary ASCVD prevention, aspirin use has a small net benefit in those aged 40-59 with a ≥10% ten-year risk of ASCVD, but not in those age 60+.
👇 jamanetwork.com/journals/jama/…
Also included:
Treatment & dosing schedule that optimizes efficacy & avoids drug interactions
I also discuss:
Dosing for both adults AND kids
How to optimize absorption w/ low bioavailable supps
When/how to take
Drug interactions when applicable
Brands
How one might combine all 12 of the treatments covered if desired
in vitro vs in vivo concentrations & calculations
etc